Jonathan Douxfils: In Contraception for Healthy Women, Safety Must Remain the Leading Criterion
Jonathan Douxfils, Director of the Clinical Pharmacology and Toxicology Research Unit at University of Namur, Board Member of Belgian Society on Thrombosis and Haemostasis, shared on LinkedIn:
”’We are in fact proposing cheaper EE-based pills, including EE/LNG, with a higher VTE risk, the perspective matters!’
From Rome to Budapest
After a great ISGE – International Society of Gynecological Endocrinology meeting in Rome, I travelled on Friday to Budapest to speak on Saturday at a symposium organized by Gedeon Richter, alongside Prof. Johannes Ott, Prof. Lorenz Küssel, and PD Dr. Monika Wolfler.
It was a real pleasure to exchange on such an important topic with colleagues deeply committed to women’s health
One message is becoming increasingly difficult to ignore: in contraception for healthy women, safety must remain the leading criterion.
For years, EE-based pills have often been perceived as the ‘reference’, while Natural Estrogens were presented as newer options with a safer profile, but at a slightly higher cost.
But what if the paradigm is actually the opposite?
If natural estrogens are considered the true reference — as proposed by the ESCONEC group — then the perception changes completely.
We are no longer proposing a somewhat more expensive pill with improved safety.
We are in fact proposing cheaper EE-based pills, including EE/LNG, with a higher VTE risk.
And when the difference may represent less than €0.40 per day, the discussion looks very different for both prescribers and patients.
In an area involving healthy women, accepting avoidable thrombotic risk should never be trivial — especially when efficacy, bleeding profile, tolerability, well-being, and quality of life are also excellent with these newer options.
This is why the way we frame the benefit–risk balance really matters.
It is probably time to rethink what should truly be considered the standard in contraceptive prescribing.
Many thanks to the audience for the warm welcome and stimulating discussions, and to the other speakers for this excellent symposium
Thank you also Gedeon Richter Austria – Christina Thaller, Irene Karas and Petra Hebar for the organization of this symposium!”

Stay updated with Hemostasis Today.
-
Aug 14, 2026, 13:43Edward Lee Carter: Optimizing Anticoagulation in Cirrhosis Beyond the Lab Numbers
-
Aug 14, 2026, 13:39Amr Saad: What Tips You Toward Cerebral Venous Thrombosis Over IIH?
-
Aug 14, 2026, 13:28Eduardo Medronha: DIPS as a Rescue Strategy in Budd–Chiari Syndrome
-
Aug 14, 2026, 13:18Immune Checkpoint Inhibitors Have Transformed Cancer Treatment – RPTH Journal
-
Aug 14, 2026, 13:04Mohammed M. Aboudeif: Cerebral Venous Thrombosis – Think Early, Treat Decisively
-
Aug 14, 2026, 12:49Ahmed Hawash: The Hawash Method for Managing Extreme ICU Complexity
-
Aug 14, 2026, 12:42Why Unfractionated Heparin Still Matters in Modern Anticoagulation – Thrombosis Canada
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma